Yasons Chemex Care manufactures and trades dyes, pigment pastes, and chemical intermediates primarily for the textile and printing industries, while also producing a small range of FMCG personal care products like hair oils and soaps.
The company operates in a highly fragmented, commodity-driven chemical market with no evidence of brand power or cost advantage, as reflected by low net margins of 5.1% and a significant decline in EPS despite rising revenues.
Capital has been deployed into working capital and an investment in a subsidiary LLP, but the negative cash conversion and declining earnings per share suggest that reinvested capital is not yet generating value for shareholders.
The company succumbed to a classic growth trap where rising revenues masked a hollow core. By 2029, the disconnect between sales and profits widened as the business continued to burn cash to fund working capital for low-margin commodity trades. The lack of internal controls and the absence of an internal auditor eventually led to a major accounting restatement when the discrepancies between bank filings and actual books became untenable. As the promoter-linked transactions drained the remaining liquidity, the company was left with stagnant earnings and a depleted capital base, proving that revenue growth without earnings or cash flow is merely a path to insolvency.
RichFakir rates Yasons Chemex Care Ltd's business quality as poor — 32/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Yasons Chemex Care Ltd is trading about 6% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Yasons Chemex Care Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Yasons Chemex Care Ltd's fair value is about ₹8 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →